Introduction: Very low-risk prostate cancer (PCa) is being increasingly managed by active surveillance (AS). Our aim was to assess the influence of the origin of diagnosis on PCa characteristics and treatment rates among men with very low-risk PCa in our prospective AS cohort. Methods: Overall, 191 men with very low-risk PCa fulfilling Epstein-criteria underwent protocol-based AS. These men originated either from the prospective population-based screening program (P-AS) or were diagnosed by opportunistic screening (O-AS). Results: Overall, n = 86 (45.0%) originated from the P-AS group, whereas n = 105 (55.0%) from the O-AS group. On univariate Cox regression analysis, age (HR 0.96, 95% CI 0.92-1.00; p = 0.05), origin of diagnosis (HR 0.72, 95% CI 0.41-1.28; p = 0.001), number of positive cores (HR 2.15, 95% CI 1.18-3.90; p = 0.01) and maximum core involvement (HR 1.03, 95% CI 0.99-1.05; p = 0.05) were predictors for treatment necessity. On multivariate analysis, age (HR 0.95, 95% CI 0.89-0.99; p = 0.05), number of positive cores (HR 2.07, 95% CI 1.10-3.88; p = 0.02), maximum core involvement (HR 1.03, 95% CI 1.00-1.06; p = 0.04) but not origin of diagnosis were independent predictors for treatment necessity. Four men developed biochemical recurrence (all from O-AS group [p = 0.05]). Conclusion: The origin of PCa diagnosis in men undergoing AS had no influence on disease progression and treatment necessity.

Keywords:
Active surveillance, Treatment rate, Opportunistic screening, Population-based screening, Very low-risk prostate cancer, Biochemical recurrence
1.
Gilfrich C, May M, Braun KP, Lebentrau S, Lehsnau M, Ecke T, Schmailzl KJ, Al-Dumaini S, Hallmann S, Ahmed AM, Maurer J, Karl T, Braun V, Haferkamp A, Brookman-May S, Bauer RM, Stief CG, Hoschke B, Maurer O, Wolff I: Evaluating the use of prostate-specific antigen as an instrument for early detection of prostate cancer beyond urologists: results of a representative cross-sectional questionnaire study of general practitioners and internal specialists. Urol Int 2014;93:160-169.
2.
van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC: Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol 2014;65:1023-1031.
3.
Seiler D, Randazzo M, Klotz L, Grobholz R, Baumgartner M, Isbarn H, Recker F, Kwiatkowski M: Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort. BJU Int 2012;110:195-200.
4.
Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB: Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006;98:355-357.
5.
Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS: Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976-983.
6.
Alonzo DG, Mure AL, Soloway MS: Prostate cancer and the increasing role of active surveillance. Postgrad Med 2013;125:109-116.
7.
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Paez A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-990.
8.
Tuppin P, Samson S, Perrin P, Ruffion A, Millat B, Weill A, Ricordeau P, Allemand H: [prostate-specific antigen use among men without prostate cancer in France (2008-2010)]. Bull Cancer 2012;99:521-527.
9.
Nordstrom T, Aly M, Clements MS, Weibull CE, Adolfsson J, Gronberg H: Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol 2013;63:419-425.
10.
Van der Meer S, Lowik SA, Hirdes WH, Nijman RM, Van der Meer K, Hoekstra-Weebers JE, Blanker MH: Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review. BMC Fam Pract 2012;13:100.
11.
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC: Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-132.
12.
Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-131.
13.
Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB: Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185-2190.
14.
Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boeve ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strolin P, van Muilekom E, Schroder FH, Bangma CH, Roobol MJ: Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013;63:597-603.
15.
Epstein JI, Walsh PC, Carmichael M, Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
16.
Kwiatkowski M, Huber A, Stamm B, Lehmann K, Wernli M, Hafeli A, Recker F: Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland. BJU Int 2003;92(suppl 2):44-47.
17.
Glass AS, Cowan JE, Fuldeore MJ, Cooperberg MR, Carroll PR, Kenfield SA, Greene KL: Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology 2013;82:60-65.
18.
Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007;178:S14-S19.
19.
Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R: Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014;65:1046-1055.
20.
Park HJ, Ha YS, Park SY, Kim YT, Lee TY, Kim JH, Lee DH, Kim WJ, Kim IY: Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+4 prostate cancers at biopsy: finding a new group eligible for active surveillance. Urol Int 2013;90:301-305.
21.
Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M: Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008;101:165-169.
22.
Becker A, Seiler D, Kwiatkowski M, Kluth LA, Schnell D, Graefen M, Schlomm T, Fisch M, Recker F, Weissbach L, Chun FK: A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center. World J Urol 2014;32:891-897.
23.
Kitagawa Y, Ueno S, Izumi K, Kadono Y, Konaka H, Mizokami A, Namiki M: Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening. J Cancer Res Clin Oncol 2014;140:53-59.
24.
Welty CJ, Carroll PR: The ongoing need for improved risk stratification and monitoring for those on active surveillance for early stage prostate cancer. Eur Urol 2014;65:1032-1033.
25.
Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ: Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011;59:893-899.
26.
Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC: Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810-2816.
27.
Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schroder F: Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009;55:1321-1330.
28.
Finelli A, Trottier G, Lawrentschuk N, Sowerby R, Zlotta AR, Radomski L, Timilshina N, Evans A, van der Kwast TH, Toi A, Jewett MA, Trachtenberg J, Fleshner NE: Impact of 5alpha-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urology 2011;59:509-514.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.